C&EN, November 13, 2017
Loures, Portugal, December 17th, 2014 – Hovione today announced that the U.S. Food and Drug Administration (FDA) performed a Pre-Approval Inspection to its plant in Loures, Portugal, covering two NDA filings. At the conclusion of the inspection, the FDA issued a Form 483 with three inspectional observations.
The inspection carried out by the FDA Investigator Mr. Ramon Hernandez and by the Chemist, Mr. Jose A. Lopez Rubet, lasted 5 days as initially planned, started on 1st December and concluded on the 5th. The inspection confirmed the site to be compliant with the principles and guidelines of Good Manufacturing Practices (GMP).
On the outcome of the inspection, Luisa Paulo, Hovione's Compliance Director, said "Addressing these observations is the top priority of the site management and the points raised will be replied to within 15 working days from the receipt of the Form 483. We are taking this result to improve our quality system both here and at our other sites. The investigators spoke positively of many of our initiatives. We have a strong pipeline of products under development with new NDAs being filed in the next 12 months, and we need to work diligently to continue to deserve our clients’ trust”.
“We have a culture of quality that puts patient safety first. This shapes our behaviors and motivates us to improve. This is a Team effort, and I am very encouraged to see everyone so committed.” said Guy Villax, Chief Executive.
Hovione is an international company with over 50 years’ experience in the development and compliant manufacture of Active Pharmaceutical Ingredients and Drug Product Intermediates. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers, in the most regulated markets. The company also offers branded pharmaceutical customers services for the development and compliant manufacture of innovative new drugs, is able to support highly potent compounds and offers proprietary product development and licensing opportunities for drug products. In the inhalation area, Hovione is the only independent company offering such a broad range of services. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards. www.hovione.com